CN118892446A - 一种含vvn001的眼科组合物 - Google Patents
一种含vvn001的眼科组合物 Download PDFInfo
- Publication number
- CN118892446A CN118892446A CN202310476403.2A CN202310476403A CN118892446A CN 118892446 A CN118892446 A CN 118892446A CN 202310476403 A CN202310476403 A CN 202310476403A CN 118892446 A CN118892446 A CN 118892446A
- Authority
- CN
- China
- Prior art keywords
- acid
- sodium
- ophthalmic
- ophthalmic composition
- citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310476403.2A CN118892446A (zh) | 2023-04-27 | 2023-04-27 | 一种含vvn001的眼科组合物 |
| PCT/CN2023/096273 WO2024221527A1 (zh) | 2023-04-27 | 2023-05-25 | 一种含vvn001的眼科组合物 |
| KR1020247022421A KR20240159657A (ko) | 2023-04-27 | 2023-05-25 | Vvn001을 함유하는 안과 조성물 |
| CA3238321A CA3238321A1 (en) | 2023-04-27 | 2023-05-25 | A vvn001-containing ophthalmic composition |
| AU2023361985A AU2023361985B2 (en) | 2023-04-27 | 2023-05-25 | A vvn001-containing ophthalmic composition |
| JP2023560923A JP2025516407A (ja) | 2023-04-27 | 2023-05-25 | Ｖｖｎ００１含有眼科組成物 |
| EP23887181.8A EP4702974A1 (en) | 2023-04-27 | 2023-05-25 | Ophthalmic composition containing vvn001 |
| TW112140586A TW202442220A (zh) | 2023-04-27 | 2023-10-24 | 一種含vvn001的眼科組合物 |
| IL312531A IL312531A (en) | 2023-04-27 | 2024-05-01 | Preparations for intraocular administration containing VVN001 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310476403.2A CN118892446A (zh) | 2023-04-27 | 2023-04-27 | 一种含vvn001的眼科组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118892446A true CN118892446A (zh) | 2024-11-05 |
Family
ID=93255459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310476403.2A Pending CN118892446A (zh) | 2023-04-27 | 2023-04-27 | 一种含vvn001的眼科组合物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4702974A1 (https=) |
| JP (1) | JP2025516407A (https=) |
| KR (1) | KR20240159657A (https=) |
| CN (1) | CN118892446A (https=) |
| AU (1) | AU2023361985B2 (https=) |
| CA (1) | CA3238321A1 (https=) |
| IL (1) | IL312531A (https=) |
| TW (1) | TW202442220A (https=) |
| WO (1) | WO2024221527A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0589020A4 (en) * | 1992-03-18 | 1994-07-06 | Coopervision Pharma | Verapamil hcl formulation and other ophthalmic solutions with buffer system for ocular administration |
| US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| HUE059052T2 (hu) * | 2014-11-07 | 2022-10-28 | Santen Pharmaceutical Co Ltd | Vizes szemészeti készítmény |
| WO2019001171A1 (zh) * | 2017-06-27 | 2019-01-03 | 维眸生物科技上海有限公司 | 一种含磷化合物及其制备和应用 |
| CN109134533B (zh) * | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| CN114533652B (zh) * | 2018-09-25 | 2024-12-13 | 沈阳兴齐眼药股份有限公司 | 药物组合物、其制备方法和用途 |
| US20230172946A1 (en) * | 2019-08-18 | 2023-06-08 | Iview Therapeutics, Inc. | In-situ Gel Forming Ophthalmic Formulations Containing Difluprednate |
| IT202000027155A1 (it) * | 2020-11-12 | 2022-05-12 | Sifi Spa | Formulazione a base di poliesametilene biguanide per il trattamento della cheratite da acanthamoeba |
| PL4312986T3 (pl) * | 2021-04-01 | 2025-02-17 | Active Biotech Ab | Preparat lakwinimodu do stosowania do oczu |
-
2023
- 2023-04-27 CN CN202310476403.2A patent/CN118892446A/zh active Pending
- 2023-05-25 CA CA3238321A patent/CA3238321A1/en active Pending
- 2023-05-25 AU AU2023361985A patent/AU2023361985B2/en active Active
- 2023-05-25 KR KR1020247022421A patent/KR20240159657A/ko active Pending
- 2023-05-25 JP JP2023560923A patent/JP2025516407A/ja active Pending
- 2023-05-25 WO PCT/CN2023/096273 patent/WO2024221527A1/zh not_active Ceased
- 2023-05-25 EP EP23887181.8A patent/EP4702974A1/en active Pending
- 2023-10-24 TW TW112140586A patent/TW202442220A/zh unknown
-
2024
- 2024-05-01 IL IL312531A patent/IL312531A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202442220A (zh) | 2024-11-01 |
| EP4702974A1 (en) | 2026-03-04 |
| JP2025516407A (ja) | 2025-05-30 |
| AU2023361985A1 (en) | 2024-11-14 |
| KR20240159657A (ko) | 2024-11-05 |
| CA3238321A1 (en) | 2025-07-08 |
| AU2023361985B2 (en) | 2025-08-14 |
| IL312531A (en) | 2024-11-01 |
| WO2024221527A1 (zh) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2436568C2 (ru) | Самоконсервирующиеся водные фармацевтические композиции | |
| US4100271A (en) | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes | |
| US4188373A (en) | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes | |
| US20140302146A1 (en) | Ophthalmic Aqueous Composition | |
| US10517869B2 (en) | Topical brimonidine tartrate ophthalmic solution | |
| EP2653155A1 (en) | Ophthalmic composition for contact lens | |
| US11541036B2 (en) | Oxymetazoline compositions | |
| JP2025074239A (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
| CN101516332B (zh) | 自身防腐的水性药物组合物 | |
| KR20110104367A (ko) | 무보존제 안과용 조성물 | |
| CN118892446A (zh) | 一种含vvn001的眼科组合物 | |
| JP2025516407A5 (https=) | ||
| HK40113077A (zh) | 一种含vvn001的眼科组合物 | |
| KR20230145458A (ko) | 우르소데옥시콜산 또는 그 염을 함유하는 수성 의약 조성물 | |
| US20260060973A1 (en) | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | |
| WO2024221524A1 (zh) | 一种用于治疗非感染性炎症疾病的眼科组合物 | |
| RU2820596C2 (ru) | Композиции оксиметазолина и способы для лечения офтальмологических расстройств | |
| HK40113256A (zh) | 一种用於治疗非感染性炎症疾病的眼科组合物 | |
| CN118340775A (zh) | 一种含vvn539的眼用组合物及其用途 | |
| KR20250064683A (ko) | 안구 충혈 완화를 위한 아프라클로니딘을 포함하는 약제학적 조성물 | |
| WO2024034592A1 (ja) | Ｕｄｃａまたはその塩を含有する水性医薬組成物 | |
| HK1186395A (en) | Ophthalmic composition for contact lens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40113077 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Country or region after: China Address after: 325035, Room 4020, Building B, Gene Medicine Valley North District, Ouhai District, Wenzhou City, Zhejiang Province Applicant after: Weimou Biotechnology (Zhejiang) Co., Ltd. Address before: 325006, Room 4020, Building B, Gene Medicine Valley North District, Ouhai District, Wenzhou City, Zhejiang Province Applicant before: Weimu Biotechnology (Zhejiang) Co.,Ltd. Country or region before: China |
|
| CB02 | Change of applicant information |